As DIAGEN Biotech Inc. , our main goal is to develop and continuously improve the services we provide in the field of production of In Vitro Diagnostic Medical Devices in a manner that is scientifically and technically appropriate.

In line with this goal, we are committed to working with our expert, competent, and friendly team who are delighted to engage in the following activities:

To achieve these objectives, we are committed to the following activities with our dedicated team:

1. Providing reliable and high-quality product services and continuously improving service quality in line with current scientific advancements.

2. Considering and evaluating customer and staff requests, engaging in improvement activities, and aiming for stakeholder satisfaction under all circumstances.

3. Instilling a culture of quality service in all departments of management and personnel, and ensuring employee participation in quality improvement activities through training programs.

4. Striving to be a company that continuously generates knowledge with well-trained personnel who are familiar with quality management system documentation and its implementation.

5. Adhering to independence, impartiality, and confidentiality principles in production and service delivery, adopting unbiased, scientifically based, and technically sound professional practices in service delivery.

6. Conducting research and development activities in line with scientific ethics by closely monitoring technological developments.

7. Fulfilling obligations arising from current laws.

8. Ensuring effective and efficient use of resources.

9. Adopting an Environmental Management System and fulfilling its requirements to systematically and regularly ensure environmental awareness in all fields of activity and to ensure the continuity of the system.

10. Continuously improving our quality and management system in accordance with international standards such as TS EN ISO 13485:2016, TS/EN ISO 9001:2015, TS/EN ISO 14001:2015, and the requirements of the Regulation on In Vitro Diagnostic Medical Devices (2017/746), as well as scientific and technological innovations.